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June 2, 2009:2101–7de (2) and a fall in HR (1). Thus, a low HR would be linked to a
igh central pressure.
In contrast, second-line beta-blockade alongside a first-line
gent that improves vascular compliance and lowers central pres-
ures in the elderly (e.g., a low-dose diuretic or calcium antagonist
4]), is linked to highly significant falls in CV end points as in the
HEP (Systolic Hypertension in the Elderly Program), ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
ttack Trial), and MRC (Medical Research Council)-Elderly (2)
tudies.
The next 2 main contributor trials (1) were the IPPPSH
International Prospective Primary Prevention Study in Hyperten-
ion) and HAPPHY (Heart Attack Primary Prevention in Hyper-
ension) trials involving young/middle-aged hypertensive patients.
he first-line beta-blockers were nonselective oxprenolol and
artially beta-1 selective atenolol/metoprolol—beta-blockers that
ower blood pressure in different ways (5). Metoprolol and atenolol
ct via a fall in HR and cardiac output; oxprenolol acts via a modest
all in HR and cardiac output plus a modest fall in peripheral
esistance via beta-2 intrinsic sympathomimetic activity. Thus,
inking a final HR or HR difference with CV events is unhelpful.
or atenolol/metoprolol, quoting intra-trial (rather that end-trial)
hanges in HR (if known) would be useful, enabling HR/CV-
vent relationships to be studied.
Cigarette smoking is another relevant, vital issue for younger
nd middle-aged hypertensive patients, as significant benefit with
xprenolol (IPPPSH), propranolol (MRC-1), and metoprolol
MAPHY [Metoprolol Atherosclerosis Prevention in Hyperten-
ives]) occurred only in nonsmokers (2). Nonsmokers (70% of the
hole) in MRC-1 experienced a significant 38% reduction in CV
vents on propranolol, similar to the results of atenolol versus
ess-tight blood pressure control in overweight middle-aged hy-
ertensive patients with type-2 diabetes in the UKPDS (United
ingdom Prospective Diabetes Study) (6,7), in which all 7 hard
nd point trends (including myocardial infarction and stroke)
avoring the beta-blockers over the angiotensin-converting enzyme
nhibitor at 9-year follow-up (7), strengthened over 20-year
ollow-up, achieving significance in the case of all-cause death (8).
moking induces epinephrine release (9) and in the presence of
eta-1/beta-2 blockade, unopposed alpha stimulation occurs; the
esultant increase in blood pressure induces reflex falls in HR (10).
n such a scenario, a low HR would be linked to an increase in CV
vents. Such a worrisome beta-blocker-epinephrine interaction is
ot observed with high beta-1 selectivity (e.g., bisoprolol) (11).
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e thank the several authors who wrote a letter concerning our
ecent paper (1).
. Dr. Phillips’s criticism of our observation, being possibly the
result of confounding by indication, needs to be considered
carefully. Although we do not have definitive evidence to rule
this out, we think it is unlikely because in our data, there was
poor correlation between heart rate achieved at the end of
treatment and the systolic blood pressure difference between the
treatment modalities (r  0.154; p  0.717). Similarly, there
was no correlation between heart rate achieved and diastolic blood
pressure difference between treatment modalities (r  0.255;
p  0.542). This would indicate that the negative chronotropic
effect of beta-blockade can, to some extent, be dissociated from
its antihypertensive effect. However, as Dr. Phillips indicates,
the only way to rule out confounding by indication would be in
looking at the individual patient data, which obviously is no
longer possible.
. We agree with Drs. Aursnes and Osnes as well as with Dr.
Cockcroft that most of the findings in all meta-analyses of
beta-blocker trials are driven by atenolol. However, atenolol
remains the most widely prescribed beta-blocker worldwide,
with more than 40 million prescriptions per year in the U.S.
alone. No head-to-head comparisons of atenolol with other
beta-blockers have been done. Until we have convincing mor-
bidity and mortality data in trials done with beta-blockers other
than atenolol, we should not automatically exculpate these
agents. Thus, it is high time to sound the death knell for
atenolol, as Dr. Cockcroft suggests, but we should continue
prescribing beta-blockers (particularly those with a better he-
modynamic and metabolic profile) for well-defined cardiovas-
cular indications.
. We take issue with Dr. Gupta’s statement that our study merely
seeks “to convert a small-to-moderate statistical relative risk
into an absolute biological risk with important practical impli-
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June 2, 2009:2101–7cations.” The inefficacy of beta-blockers to prevent heart attack
and stroke in hypertension patients has been extensively docu-
mented and, at least for atenolol, is beyond any doubt. Dr.
Gupta’s point that beta-blockers specifically may prevent head-
aches, which are common in hypertension, has not been
substantiated by data. Headaches have been clearly shown to be
less common with all antihypertensive therapy (regardless of
class) than with placebo (2).
. Drs. Laurent and Boutouyrie’s reanalysis of data from our
meta-analysis indicates that heart rate at baseline (before
antihypertensive therapy) may have acted as a confounding
factor in our analysis. We obviously cannot rule this possibility
out, but we would like to point out that a subanalysis of the
CAFE (Conduit Artery Function Evaluation) study extended
and corroborated our findings (3). Moreover, analyses of our
data done with cardiovascular outcomes as a function of the
mean heart rate reduction (baseline minus end of treatment)
with beta-blockers also showed similar relationships, that is, the
greater the reduction of heart rate was with beta-blockers, the
higher the risk was of cardiovascular events.
. The point of Dr. Khan, that beta-blockers are less effective at
preventing cardiovascular events than other antihypertensive
agents, is correct. We do not think that beta-blockers actually
increase cardiovascular events. However, despite a fall in blood
pressure, they do not decrease cardiovascular events in hyper-
tensive patients, thereby providing a false sense of security to
patients and physicians: blood pressure is controlled, yet risks of
heart attack and stroke remain unchanged. Pooled analyses
report that beta-blockers reduce the risk of stroke by 16% to
22% when compared with placebo. However, this risk reduction
is suboptimal compared with the 38% reduction for the same
degree of blood pressure reduction observed with the use of
other antihypertensive agents (4).
. We agree with Dr. Fragasso and colleagues that not all
beta-blockers are created equal. Some of the newer agents such
as nebivolol and carvedilol are metabolically and hemodynam-
ically more patient friendly than the traditional agents and do
not impair endothelial function. However, outcomes data with
newer beta-blockers in hypertension are lacking, so it remains
uncertain whether these benefits of surrogate end points will
result in benefits of morbidity and mortality.
5. Dr. Cruikshank has an established track record of aggressively
defending beta-blockers. He is correct though in that the MRC
(Medical Research Council) study showed some benefits of
propranolol in average 47-year-old male British smokers. This
finding was the result of much data dredging; in the main study
there was no difference in all-cause mortality, heart attack, and
stroke between propranolol and placebo. In the same MRC
studies, twice as many patients dropped out because of adverse
events on beta-blockers than on diuretics. In fact, these studies
allow us to calculate that for every heart attack or stroke
prevented, 3 patients were made impotent by beta-blockers and
8 experienced fatigue to the extent that they withdrew from the
study (5). This seems hardly an acceptable risk-to-benefit ratio
for patients with a completely asymptomatic disease such as
stage I essential hypertension.
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